Want to see DE:MED full AI Analyst Report?

MEDICLIN (MED) Price & Analysis

1 Followers

MED Stock Chart & Stats

€4.26

-€0.10(-2.35%)

At close: Jul 27 4:00 PM EDT

€4.26

-€0.10(-2.35%)

Day’s Range― - ―

52-Week Range€2.88 - €4.26

Previous CloseN/A

Volume15.80K

Average Volume (3M)5.25K

Market Cap

€194.75M

Enterprise Value€467.05

Total Cash (Recent Filing)€152.40M

Total Debt (Recent Filing)€384.07M

Price to Earnings (P/E)6.9

Beta0.24

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.97%

Share Statistics

EPS (TTM)0.60

Shares Outstanding47,500,000

10 Day Avg. Volume4,347

30 Day Avg. Volume5,253

Financial Highlights & Ratios

PEG Ratio1.78

Price to Book (P/B)0.71

Price to Sales (P/S)0.22

P/FCF Ratio3.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.78

Revenue Forecast (FY)€805.60M

Bulls Say, Bears Say

Bulls Say

Revenue And Operating RecoveryA 26% TTM revenue rise with positive EBIT and net margins signals a durable operational recovery versus prior losses. Stronger top-line and regained profitability increase cash flow potential, support reinvestment in facilities, and reduce structural execution risk over months.

Consistent Cash GenerationStable operating cash flow (~€94m) and positive free cash flow (~€49m) provide recurring internal funding for capex, working capital and gradual deleveraging. Reliable cash generation underpins financial flexibility and funds operational improvements without immediate external financing.

Recovered Return On EquityROE recovery to ~11.9% reflects improving profitability and more efficient capital use after a loss year. Sustained positive ROE supports long-term shareholder value creation, indicates management execution, and helps rebuild capital buffers to address leverage.

Bears Say

Elevated LeverageA debt-to-equity ratio near 1.46x limits balance-sheet flexibility and raises refinancing and interest-rate sensitivity. Elevated leverage can constrain strategic investment, slows ability to respond to shocks, and makes sustained margin deterioration more damaging to credit metrics.

Thin And Volatile MarginsRelatively slim net and EBIT margins leave limited buffer against cost or reimbursement pressures. Historical volatility (including a loss in 2023) undermines earnings predictability, complicates planning for capex, staffing, and debt reduction over the medium term.

Weak FCF Conversion And Slowing FCF GrowthNegative FCF growth and FCF about half of net income indicate modest conversion quality. This limits the speed of deleveraging, constrains reinvestment without external funding, and reduces resilience to operational setbacks over the next several quarters.

MED FAQ

What was MEDICLIN AG’s price range in the past 12 months?

MEDICLIN AG lowest stock price was €2.88 and its highest was €4.26 in the past 12 months.

What is MEDICLIN AG’s market cap?

MEDICLIN AG’s market cap is €194.75M.

When is MEDICLIN AG’s upcoming earnings report date?

MEDICLIN AG’s upcoming earnings report date is Nov 05, 2026 which is in 95 days.

How were MEDICLIN AG’s earnings last quarter?

MEDICLIN AG released its earnings results on Jul 30, 2026. The company reported €0.206 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is MEDICLIN AG overvalued?

According to Wall Street analysts MEDICLIN AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MEDICLIN AG pay dividends?

MEDICLIN AG pays a Annually dividend of €0.04 which represents an annual dividend yield of 0.97%. See more information on MEDICLIN AG dividends here

What is MEDICLIN AG’s EPS estimate?

MEDICLIN AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MEDICLIN AG have?

MEDICLIN AG has 47,500,000 shares outstanding.

What happened to MEDICLIN AG’s price movement after its last earnings report?

MEDICLIN AG reported an EPS of €0.206 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.966%.

Which hedge fund is a major shareholder of MEDICLIN AG?

Currently, no hedge funds are holding shares in DE:MED

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

MEDICLIN Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

0.97%

Trailing 12-Months

Asset Growth

-6.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

MEDICLIN AG

Mediclin AG is a German healthcare enterprise primarily engaged in managing hospitals across the nation. Its operations are categorized into three main segments: Post-Acute, Acute, and various other related activities. The company offers a comprehensive range of medical specializations, encompassing fields such as neurology, psychosomatics, orthopaedics, internal medicine, cardiology, oncology, geriatrics, psychiatry, and surgical interventions, in addition to general nursing care. Furthermore, Mediclin provides specialized services like ear, nose, and throat (ENT) treatment and acute outpatient care. As of December 31, 2021, its extensive network comprised 34 clinics, 7 nursing care facilities, and 11 medical care centres. This infrastructure collectively provided a significant capacity of 7,831 beds and 482 nursing places, distributed across eleven of Germany's federal states. The company's corporate headquarters are situated in Offenburg, Germany.